FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2735078070> ?p ?o ?g. }

• W2735078070 endingPage "537" @default.
• W2735078070 startingPage "537" @default.
• W2735078070 abstract "Abstract Introduction: Phase 3 trials demonstrated maintenance therapy after autologous stem cell transplant (ASCT) extended time to progression, progression-free survival, and in some cases overall survival for patients (pts) with multiple myeloma (MM) (Sonneveld, 2012; McCarthy, 2012; Attal, 2012; Palumbo, 2014; Attal, 2016). Maintenance treatment until progression has the potential to adversely impact health-related quality of life (HRQoL). Few HRQoL analyses have been published in MM, especially with regard to maintenance therapy after ASCT. Connect® MM is the first and largest multicenter, US-based, prospective observational cohort study designed to characterize treatment patterns and outcomes for pts with newly diagnosed MM (NDMM). This analysis evaluated HRQoL of pts who received Any maintenance therapy, lenalidomide (LEN) only, or No maintenance post-ASCT. Methods: Pts ≥ 18 years with NDMM within 60 days of diagnosis were eligible for enrollment in the registry. For this analysis, pts who completed induction therapy and first-line ASCT who may or may not have gone on to receive maintenance (yes/no) were included. Pts were evaluated in 3 groups: Any maintenance (including LEN-only), LEN-only maintenance, and No maintenance. Pt-reported HRQoL data were collected at protocol-defined quarterly visits. The primary HRQoL measure analyzed was the EQ-5D Index score. Secondary measures included the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) total score and the Brief Pain Inventory (BPI). HRQoL assessments were analyzed at study entry (study baseline); after induction therapy but prior to ASCT (analytic baseline); and quarterly from 100 days post-ASCT until the end of maintenance (maintenance groups) or until progressive disease, discontinuation, or death (all groups) (analytic period). SAS Proc Mixed with a random effects unstructured covariance matrix was used to estimate mixed regression models to test the null hypothesis of no HRQoL difference between pts receiving Any or LEN-only maintenance vs No maintenance. A quadratic growth model was used with time as a continuous variable (given that ASCT can occur at any fractional quarterly period post-enrollment and having a starting at 100 days post-ASCT), adjusted for potential confounders. Results: Between September 2009 and December 2011, Connect® MM enrolled 1493 pts in Cohort 1 from community (82%) and academic (17%) centers. Of the 540 pts who received ASCT, 238 met the analysis criteria for Any maintenance, 167 for LEN-only, and 138 for No maintenance. Median age (range) was 60 years (24-78); 61% were male, and 85% were white. The majority were Eastern Cooperative Oncology Group performance status 0/1 (64%) and International Staging System stage I/II (56%). A higher proportion of pts in the Any and LEN-only maintenance groups received triplet therapy as induction vs the No maintenance group (64%, 66%, and 51%, respectively). Median duration (range) of maintenance in the Any and LEN-only maintenance groups was 23.0 months (0.8-50.4) and 24.4 months (0.6-50.4), respectively. During the analytic period, the EQ-5D questionnaire completion rate across the 3 comparison groups was similar and decreased at a similar rate over time. The median number (range) of EQ-5D forms completed per patient was 4.5 (1.0-16.0), 5.0 (1.0-15) and 5.0 (1.0-16.0) for Any, LEN-only, and No maintenance groups, respectively. The mean baseline HRQoL scores for each measure were similar across the 3 groups, with ranges of EQ-5D (0.75-0.76), FACT-MM Total (114.8-119.7), and BPI (3.87-4.06). There were no significant differences in estimated mean post-ASCT scores when comparing Any or LEN-only with the No maintenance group for the EQ-5D Overall Index, the FACT-MM Total Score, or the BPI (Table and Figure). Conclusions: NDMM pts in the Connect® MM registry receiving Any or LEN-only maintenance therapy vs No maintenance after ASCT demonstrated generally similar HRQoL scores for the EQ-5D Index, FACT-MM, and BPI. These results suggest that there is no difference in HRQoL for those who received maintenance compared with those who did not despite the risks associated with continued active therapy. Save Disclosures Abonour: Celgene: Membership on an entity's Board of Directors or advisory committees. Jagannath:Bristol-Myers Squibb: Consultancy; Celgene: Consultancy; Merck: Consultancy. Terebelo:Celgene: Membership on an entity's Board of Directors or advisory committees. Gasparetto:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy; Bristol-Myers Squibb: Honoraria; Onyx: Honoraria; Janssen: Honoraria. Toomey:Celgene: Consultancy. Hardin:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees. Kitali:Celgene: Employment, Equity Ownership. Gibson:Celgene: Employment, Equity Ownership; Sanofi: Other: Spouse employment . Srinivasan:Celgene: Employment; Individual Patent: Patents & Royalties: US7,495,673B1 Used for MM-Connect Treatment Patterns Abstract.. Swern:Celgene: Employment, Equity Ownership. Rifkin:Celgene: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen/ONYX: Membership on an entity's Board of Directors or advisory committees." @default.
• W2735078070 created "2017-07-21" @default.
• W2735078070 creator A5018302007 @default.
• W2735078070 creator A5026109406 @default.
• W2735078070 creator A5028046297 @default.
• W2735078070 creator A5041503485 @default.
• W2735078070 creator A5043351209 @default.
• W2735078070 creator A5044273966 @default.
• W2735078070 creator A5047486042 @default.
• W2735078070 creator A5057254430 @default.
• W2735078070 creator A5059616971 @default.
• W2735078070 creator A5064115439 @default.
• W2735078070 creator A5066180365 @default.
• W2735078070 creator A5068510673 @default.
• W2735078070 creator A5083089947 @default.
• W2735078070 creator A5088629560 @default.
• W2735078070 date "2016-12-02" @default.
• W2735078070 modified "2023-09-26" @default.
• W2735078070 title "Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry" @default.
• W2735078070 doi "https://doi.org/10.1182/blood.v128.22.537.537" @default.
• W2735078070 hasPublicationYear "2016" @default.
• W2735078070 type Work @default.
• W2735078070 sameAs 2735078070 @default.
• W2735078070 citedByCount "13" @default.
• W2735078070 countsByYear W27350780702017 @default.
• W2735078070 countsByYear W27350780702018 @default.
• W2735078070 countsByYear W27350780702019 @default.
• W2735078070 countsByYear W27350780702020 @default.
• W2735078070 countsByYear W27350780702022 @default.
• W2735078070 crossrefType "journal-article" @default.
• W2735078070 hasAuthorship W2735078070A5018302007 @default.
• W2735078070 hasAuthorship W2735078070A5026109406 @default.
• W2735078070 hasAuthorship W2735078070A5028046297 @default.
• W2735078070 hasAuthorship W2735078070A5041503485 @default.
• W2735078070 hasAuthorship W2735078070A5043351209 @default.
• W2735078070 hasAuthorship W2735078070A5044273966 @default.
• W2735078070 hasAuthorship W2735078070A5047486042 @default.
• W2735078070 hasAuthorship W2735078070A5057254430 @default.
• W2735078070 hasAuthorship W2735078070A5059616971 @default.
• W2735078070 hasAuthorship W2735078070A5064115439 @default.
• W2735078070 hasAuthorship W2735078070A5066180365 @default.
• W2735078070 hasAuthorship W2735078070A5068510673 @default.
• W2735078070 hasAuthorship W2735078070A5083089947 @default.
• W2735078070 hasAuthorship W2735078070A5088629560 @default.
• W2735078070 hasConcept C126322002 @default.
• W2735078070 hasConcept C141071460 @default.
• W2735078070 hasConcept C143998085 @default.
• W2735078070 hasConcept C159110408 @default.
• W2735078070 hasConcept C2776063141 @default.
• W2735078070 hasConcept C2776364478 @default.
• W2735078070 hasConcept C2776694085 @default.
• W2735078070 hasConcept C2778283404 @default.
• W2735078070 hasConcept C2779050716 @default.
• W2735078070 hasConcept C2779951463 @default.
• W2735078070 hasConcept C71924100 @default.
• W2735078070 hasConceptScore W2735078070C126322002 @default.
• W2735078070 hasConceptScore W2735078070C141071460 @default.
• W2735078070 hasConceptScore W2735078070C143998085 @default.
• W2735078070 hasConceptScore W2735078070C159110408 @default.
• W2735078070 hasConceptScore W2735078070C2776063141 @default.
• W2735078070 hasConceptScore W2735078070C2776364478 @default.
• W2735078070 hasConceptScore W2735078070C2776694085 @default.
• W2735078070 hasConceptScore W2735078070C2778283404 @default.
• W2735078070 hasConceptScore W2735078070C2779050716 @default.
• W2735078070 hasConceptScore W2735078070C2779951463 @default.
• W2735078070 hasConceptScore W2735078070C71924100 @default.
• W2735078070 hasIssue "22" @default.
• W2735078070 hasLocation W27350780701 @default.
• W2735078070 hasOpenAccess W2735078070 @default.
• W2735078070 hasPrimaryLocation W27350780701 @default.
• W2735078070 hasRelatedWork W1851688703 @default.
• W2735078070 hasRelatedWork W2033089666 @default.
• W2735078070 hasRelatedWork W2060588247 @default.
• W2735078070 hasRelatedWork W2128084036 @default.
• W2735078070 hasRelatedWork W2496924072 @default.
• W2735078070 hasRelatedWork W2549271193 @default.
• W2735078070 hasRelatedWork W2980022578 @default.
• W2735078070 hasRelatedWork W2981240392 @default.
• W2735078070 hasRelatedWork W4252220621 @default.
• W2735078070 hasRelatedWork W4323534039 @default.
• W2735078070 hasVolume "128" @default.
• W2735078070 isParatext "false" @default.
• W2735078070 isRetracted "false" @default.
• W2735078070 magId "2735078070" @default.
• W2735078070 workType "article" @default.